RSLS - ReShape Lifesciences Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.46
-0.03 (-2.01%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.49
Open1.48
Bid1.43 x 400
Ask1.52 x 4600
Day's Range1.44 - 1.50
52 Week Range1.32 - 78.00
Volume98,529
Avg. Volume448,761
Market Cap7.285M
Beta1.85
PE Ratio (TTM)N/A
EPS (TTM)-3.07
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.00
Trade prices are not sourced from all markets
  • ReShape Lifesciences Announces $2.7 Million Registered Direct Offering Priced At-the-Market
    PR Newswire10 days ago

    ReShape Lifesciences Announces $2.7 Million Registered Direct Offering Priced At-the-Market

    SAN CLEMENTE, Calif., July 11, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 1,241,382 shares of its common stock, at a purchase price per share of $2.05, for gross proceeds of approximately $2.55 million, in a registered direct offering priced at-the-market. Additionally, ReShape Lifesciences has also agreed to issue to the investors unregistered warrants to purchase up to 1,241,382 shares of common stock, at a purchase price per warrant of $0.125, for gross proceeds of approximately $0.15 million. The warrants have an exercise price of $2.06 per share of common stock, will be exercisable immediately and will expire five and one-half years from the issuance date.

  • ReShape Lifesciences Expands Intra-gastric Balloon Business to Include Brigham and Women's Hospital in Boston
    PR Newswire11 days ago

    ReShape Lifesciences Expands Intra-gastric Balloon Business to Include Brigham and Women's Hospital in Boston

    SAN CLEMENTE, Calif., July 10, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the successful implant of the first ReShape Balloon™ at the Brigham and Women's Hospital in Boston, MA. The implant was performed by Scott Shikora, MD, Director of the Center for Metabolic and Bariatric Surgery at Brigham and Women's Hospital.  Dr. Shikora, who serves as Chief Medical Officer at ReShape Lifesciences, is also a past president of the American Society for Metabolic and Bariatric Surgery (ASMBS).

  • ReShape Lifesciences Announces Acceptance of Abstract to be Presented at IFSO Annual Conference
    PR Newswire24 days ago

    ReShape Lifesciences Announces Acceptance of Abstract to be Presented at IFSO Annual Conference

    SAN CLEMENTE, Calif., June 27, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that the company has had an abstract accepted by the scientific committee of the 23rd World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). About ReShape Lifesciences Inc. ReShape Lifesciences™ is a medical device company focused on technologies to treat obesity and metabolic diseases.

  • ReShape Lifesciences Announces $1.5 Million Registered Direct Offering Priced At-the-Market
    PR Newswirelast month

    ReShape Lifesciences Announces $1.5 Million Registered Direct Offering Priced At-the-Market

    SAN CLEMENTE, Calif., June 20, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 469,490 shares of its common stock, at a purchase price per share of $3.07, for gross proceeds of approximately $1.44 million, in a registered direct offering priced at-the-market. Additionally, ReShape Lifesciences has also agreed to issue to the investors unregistered warrants to purchase up to 469,490 shares of common stock, at a purchase price per warrant of $0.125, for gross proceeds of approximately $0.06 million. The warrants have an exercise price of $3.08 per share of common stock, will be exercisable immediately and will expire five and one-half years from the issuance date.

  • ReShape Lifesciences Receives USPTO Issue Notification for Patent Covering its ReShape Vest
    PR Newswirelast month

    ReShape Lifesciences Receives USPTO Issue Notification for Patent Covering its ReShape Vest

    SAN CLEMENTE, Calif., June 19, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announces that the United States Patent and Trademark Office ("USPTO") has issued an Issue Notification for U.S. Patent Number 10010441 entitled "Gastric Restriction Device for Treating Obesity," which covers a patent application regarding the Company's Gastric Vest System (the "ReShape VestTM"). "The ReShape Vest is a novel and ground-breaking advancement in the obesity space.  This patent allowance represents a key milestone towards our launch of this revolutionary product for patients suffering from obesity and our physician customers who treat these patients" said Dan Gladney, Chairman and Chief Executive Officer of ReShape Lifesciences™.

  • Is ReShape Lifesciences Inc (NASDAQ:RSLS) Undervalued?
    Simply Wall St.last month

    Is ReShape Lifesciences Inc (NASDAQ:RSLS) Undervalued?

    ReShape Lifesciences Inc (NASDAQ:RSLS), a medical equipment company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM over the last few months,Read More...

  • ReShape Lifesciences (RSLS) Enters Oversold Territory
    Zackslast month

    ReShape Lifesciences (RSLS) Enters Oversold Territory

    ReShape Lifesciences Inc. (RSLS) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

  • ReShape Lifesciences Announces $1.5 Million Registered Direct Offering Priced At-the-Market
    PR Newswirelast month

    ReShape Lifesciences Announces $1.5 Million Registered Direct Offering Priced At-the-Market

    SAN CLEMENTE, Calif., June 7, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 374,572 shares of its common stock, at a purchase price per share of $3.92, for gross proceeds of approximately $1.47 million, in a registered direct offering priced at-the-market. Additionally, ReShape Lifesciences has also agreed to issue to the investors unregistered warrants to purchase up to 280,929 shares of common stock, at a purchase price per warrant of $0.125, for gross proceeds of approximately $0.03 million. The warrants have an exercise price of $3.93 per share of common stock, will be exercisable immediately and will expire five and one-half years from the issuance date.

  • ReShape Lifesciences Assembles World Class Scientific Advisory Board
    PR Newswirelast month

    ReShape Lifesciences Assembles World Class Scientific Advisory Board

    SAN CLEMENTE, Calif. , June 6, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the ...

  • ReShape Lifesciences Announces New Patent Grant Expanding its Bioelectronic and Neuromodulation Portfolio
    PR Newswire2 months ago

    ReShape Lifesciences Announces New Patent Grant Expanding its Bioelectronic and Neuromodulation Portfolio

    ReShape Lifesciences recently presented results that utilized this intellectual property in a diabetic rat study that looked at the effect of multi-site electrical neuromodulation via the vagus nerve.  The study involved the simultaneous nerve pacing and neuro-blocking of two branches of the vagus nerve, innervating the pancreas and the liver, respectively, followed by continuous measurement of plasma glucose. Results showed that glycemic control was significantly increased following an elevated glucose challenge in the ReShape Lifesciences neuromodulation rats compared to those in the control group.

  • ReShape Lifesciences Provides Update on FDA Letter to Health Care Providers Related to Intragastric Balloons
    PR Newswire2 months ago

    ReShape Lifesciences Provides Update on FDA Letter to Health Care Providers Related to Intragastric Balloons

    Conference Call Scheduled for June 4, 2018 at 1:30 PM Pacific Time SAN CLEMENTE, Calif. , June 4, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical ...

  • ReShape Lifesciences Announces 1-for-15 Reverse Stock Split
    PR Newswire2 months ago

    ReShape Lifesciences Announces 1-for-15 Reverse Stock Split

    SAN CLEMENTE, Calif., June 1, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that its Board of Directors has declared a 1-for-15 reverse stock split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on June 4, 2018. At that time, each 15 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. As a result of the reverse stock split, proportional adjustments will be made to the number of shares of common stock issuable upon exercise or conversion, and the per share exercise or conversion price, of the company's outstanding warrants, stock options and convertible preferred stock, in each case in accordance with their terms.

  • ReShape Lifesciences Inc (NASDAQ:RSLS): Does The -44.76% Earnings Drop Reflect A Longer Term Trend?
    Simply Wall St.2 months ago

    ReShape Lifesciences Inc (NASDAQ:RSLS): Does The -44.76% Earnings Drop Reflect A Longer Term Trend?

    Investors with a long-term horizong may find it valuable to assess ReShape Lifesciences Inc’s (NASDAQ:RSLS) earnings trend over time and against its industry benchmark as opposed to simply looking atRead More...

  • ReShape Lifesciences to Participate at Digestive Disease Week 2018
    PR Newswire2 months ago

    ReShape Lifesciences to Participate at Digestive Disease Week 2018

    On Sunday, June 3, 2018, ReShape Lifesciences™ will be participating in two Hands-On Workshops for physicians from 9:00 AM - 11:30 AM and 1:00 PM - 3:30 PM.  These workshops will provide an opportunity for an estimated 80 physician-participants to interact with ReShape Balloon™ experts as they demonstrate the FDA-approved dual intragastric balloon device for weight loss. ReShape Lifesciences will also be participating in the ABE Annual Meeting and Reception on Friday, June 1, 2018.

  • ReShape Lifesciences Trains Eleven Surgeons in Saudi Arabia
    PR Newswire2 months ago

    ReShape Lifesciences Trains Eleven Surgeons in Saudi Arabia

    The physicians, who specialize in gastroenterology and bariatric surgery and practice in leading medical centers in Saudi Arabia, were trained by a combination of ReShape in-house customer education professionals and five seasoned representatives from the company's Saudi Arabian distribution partner. Saudi Arabia has one of the highest obesity and overweight prevalence rates in the world.

  • ReShape Lifesciences Announces Record Revenue for First Quarter 2018
    PR Newswire2 months ago

    ReShape Lifesciences Announces Record Revenue for First Quarter 2018

    SAN CLEMENTE, Calif. , May 14, 2018 /PRNewswire/ --   ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported ...

  • ACCESSWIRE2 months ago

    ReShape Lifesciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 14, 2018 / ReShape Lifesciences, Inc. (NASDAQ: RSLS ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 14, 2018 at 4:30 PM Eastern Time. ...

  • ReShape Lifesciences Announces Submission for Approval of ReShape Balloon™ in Canada
    PR Newswire2 months ago

    ReShape Lifesciences Announces Submission for Approval of ReShape Balloon™ in Canada

    SAN CLEMENTE, Calif. , May 10, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the ...

  • GlobeNewswire2 months ago

    Investor Expectations to Drive Momentum within Plains Group Holdings, EnteroMedics, Vanda Pharmaceuticals, Cinemark, EPR Properties, and The Estee Lauder Companies — Discovering Underlying Factors of Influence

    NEW YORK, May 10, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Plains ...

  • PR Newswire3 months ago

    ReShape Lifesciences to Host First Quarter 2018 Conference Call on May 14, 2018

    SAN CLEMENTE, Calif. , April 30, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced ...

  • ACCESSWIRE3 months ago

    Free Post Earnings Research Report: Senseonics' Quarterly Revenues Zoomed 867%

    Stock Monitor: ReShape Lifesciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free earnings report on Senseonics Holdings, Inc. (NYSE: ...

  • Forty Surgeons Trained on ReShape Balloon at Hands-On Course During SAGES 2018
    PR Newswire3 months ago

    Forty Surgeons Trained on ReShape Balloon at Hands-On Course During SAGES 2018

    SAN CLEMENTE, Calif., April 18, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that over 40 surgeons were trained to implant the ReShape BalloonTM during the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2018 /16th World Congress that was held in Seattle from April 11-14, 2018. ReShape Lifesciences was a participant in the Endoscopic Surgery Bariatric Endoscopy Hands-On Course that was held as part of SAGES.  One of the course objectives was for the participating endoscopic surgeons to learn to integrate emerging technologies for weight-loss into their practices through hands-on experience.  Over 40 surgeons chose to be educated and trained on the ReShape Balloon technology during the course.

  • ReShape Lifesciences Pioneers New Bio-electronic Technology for Treatment of Type 2 Diabetes
    PR Newswire3 months ago

    ReShape Lifesciences Pioneers New Bio-electronic Technology for Treatment of Type 2 Diabetes

    SAN CLEMENTE, Calif., April 10, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company will be presenting early results of a new, novel use of the ReShape Lifesciences™ neuro-blocking technology in combination with separate-site vagus nerve stimulation for the treatment of type 2 diabetes.  Results of a recent study, which examines this first-ever application for the treatment of type 2 diabetes, will be discussed in a poster presentation during the Minnesota Neuromodulation Symposium taking place at the Graduate Minneapolis Hotel from April 12-13, 2018.

  • ReShape Lifesciences Continues Expansion in Middle East with Approval of ReShape Balloon in Saudi Arabia
    PR Newswire4 months ago

    ReShape Lifesciences Continues Expansion in Middle East with Approval of ReShape Balloon in Saudi Arabia

    SAN CLEMENTE, Calif., April 3, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced approval of the Company's ReShape Balloon™ by the Kingdom of Saudi Arabia Saudi Food and Drug Authority. Congruent with this approval, the Company received an initial stocking order from Dar Al Zahrawi Medical Co LLC, KSA.